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Cancer is a complex disease that
is not well understood and alarmingly,
according to a recent UK study published
in 2015 in the British Journal of Cancer,
one in two people will be diagnosed with
the tragic disease. Understanding the
types and stages of cancer leads the way
toward generating effective and efficient
treatments. The goals of standard
cancer treatments today are incredibly
aggressive in order to rid the body of
the cancerous cells. These forms of
treatment initially appear ideal; however,
after further investigation, those methods
come with unforeseen consequences
and do not take other factors into
consideration. In order for a treatment
plan to be successful, it must deviate
from the “one size fits all” mentality
and consider the fact that cancer varies
with each individual in regard to genetic
mutations, specific protein expression,
severity, location, type and etiology of
the disease. Today’s standard treatment
methods include surgery, chemotherapy,
radiation and immunotherapy. A problem
that is common in patients receiving
these aggressive treatments is that their
healthy cells are compromised causing
adverse effects. The least recognized
yet potentially the most effective of
all methods is targeted drug therapy.
Targeted drug therapies work by
attacking specific cellular signals used by
cancer to spread, grow and communicate
without affecting healthy cells. For
example, through previous studies the
cellular signaling pathway of the gene
CD82 was discovered to suppress cancer
tumor metastasis per regulation of
proteins: c-Met and Src kinases. During
the studies, CD82 interacted with the
gene CD151 and was found to have the
opposite effects on metastasis compared
to CD82. This pathway could ideally
be targeted for the use of drug therapy;
therefore, the research on this pathway is
imperative.
The research focuses on observing
changes in protein interactions involved
in metastatic prostate cancer cells:
CD151’s association with C-met in the

presence and absence of CD82. The
results indicate that the overexpression of
CD82 in a metastatic prostate cancer cell
line significantly reduces the association
and regulation between CD151 and
C-met and thus inhibits metastasis at the
molecular level. The effectiveness of the
study was tested using two techniques
that measure the changes in protein level
expression called immunofluorescent
staining and gel electrophoresis.
Immunofluorescent staining allows for
the protein expression on the cell surface
to be visualized through fluorescent
biomarkers. Three separate sets of two
proteins were stained with antibodies to
be evaluated through immunofluorescent
staining. Set 1: CD82 with C-met;
Set 2: CD151 with C-met; and Set 3:
CD82 with CD151, cellular surface
expressions were studied. Understanding
the relationship between these three
proteins propose a greater potential
for understanding the mechanism of
metastasis. Analysis of the specific
molecules contributing to metastasis
could orchestrate the development of
successful targeted drug therapies as
treatment for cancer. The uniqueness of
this study allows for other researchers to
piece the discovered information with
known information to create a broader
understanding in the field of cancer
biology.
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